CLINICAL TRIALS PROFILE FOR XOFIGO

All Clinical Trials for XOFIGO

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00667199 ↗	BAY88-8223, Does Response Study in HRPC Patients	Completed	Bayer	Phase 2	2005-05-30	The purpose of this study is to evaluate the efficacy and safety of the investigational radioisotope Radium-223, Xofigo (Alpharadin), in treatment of men with prostate cancer and bone metastases that no longer respond to hormonal treatment.
NCT00667537 ↗	PK in Pts With HRPC & Skeletal Metastes	Completed	Bayer	Phase 1	2007-07-01	Primary objective: To investigate the biodistribution, radiation dosimetry, and pharmacokinetics of two separate intravenous (IV) injections of Xofigo (100 kBq/kg body weight [b.w.] [=110 kBq/kg based on the 2015 National Institute of Standards and Technology standardization], 6 weeks apart). Secondary objectives: To determine the safety of IV injections of Xofigo after two separate injections (6 weeks apart), to evaluate treatment response (antitumour effect in osteoblastic bone metastases) of Xofigo treatment consisting of two injections of activity 100 kBq/kg b.w. (=110 kBq/kg based on the 2015 National Institute of Standards and Technology standardization), 6 weeks apart and to evaluate long term radiation toxicity and to collect survival data at 6 and 12 months after the first injection
NCT00748046 ↗	Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton	Completed	Bayer	Phase 1	2008-08-01	The purpose of the study is to investigate the safety, biodistribution, radiation dosimetry and pharmacokinetics of three intravenous escalating dose levels of Xofigo (Alpharadin).
NCT01070485 ↗	BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease	Completed	Bayer	Phase 2	2010-01-01	The purpose of the study is to investigate if multiple (up to four) intravenous injections of Xofigo (Alpharadin) have any clinically relevant effect on bone markers in breast cancer patients with bone dominant disease who have progressed on endocrine therapy and are no longer considered suitable for endocrine therapy. In addition the safety of Xofigo (Alpharadin) will be assessed.

Clinical Trial Conditions for XOFIGO

Condition Name

Condition Name for XOFIGO
Intervention	Trials
Prostate Cancer	8
Metastatic Malignant Neoplasm in the Bone	3
Prostatic Neoplasms, Castration-Resistant	3
Castration-Resistant Prostate Carcinoma	3

Condition MeSH

Condition MeSH for XOFIGO
Intervention	Trials
Prostatic Neoplasms	24
Neoplasm Metastasis	9
Bone Marrow Diseases	5
Carcinoma	5

Clinical Trial Locations for XOFIGO

Trials by Country

Trials by Country for XOFIGO
Location	Trials
United States	82
Italy	11
United Kingdom	6
Germany	6
Spain	5

Trials by US State

Trials by US State for XOFIGO
Location	Trials
California	8
Pennsylvania	6
Michigan	5
New York	4
Ohio	4

Clinical Trial Progress for XOFIGO

Clinical Trial Phase

Clinical Trial Phase for XOFIGO
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	3
Phase 2	14

Clinical Trial Status

Clinical Trial Status for XOFIGO
Clinical Trial Phase	Trials
Completed	13
Recruiting	8
Active, not recruiting	7

Clinical Trial Sponsors for XOFIGO

Sponsor Name

Sponsor Name for XOFIGO
Sponsor	Trials
Bayer	18
National Cancer Institute (NCI)	5
M.D. Anderson Cancer Center	2

Sponsor Type

Sponsor Type for XOFIGO
Sponsor	Trials
Industry	22
Other	22
NIH	5

Clinical Trials Update, Market Analysis, and Projection for XOFIGO

Last updated: January 27, 2026

Executive Summary

XOFIGO (radium-223 dichloride) is an alpha-emitting radiopharmaceutical indicated for the treatment of castration-resistant prostate cancer (CRPC) with symptomatic bone metastases. Originally approved by the FDA in 2013, XOFIGO has established itself as a key player in prostate cancer management. This report consolidates recent clinical trial updates, market dynamics, competitive landscape, and future projections to inform stakeholders’ strategic decisions.

---

Clinical Trials Update

Current and Ongoing Clinical Trials

Trial Identifier	Phase	Title	Status	Enrollment	Focus	Sponsor	Expected Completion
NCT03561178	Phase III	ALSYMPCA in mCRPC	Completed	921	Overall survival in mCRPC with bone metastases	Bayer	2018
NCT04331007	Phase III	Radium-223 + Enzalutamide	Recruiting	600	Efficacy and safety	Bayer	2024
NCT03385655	Phase II	Radium-223 + Cabazitaxel	Active, not recruiting	150	Combination efficacy	Bayer	2023
NCT03852615	Phase III	Radium-223 + Pembrolizumab	Recruiting	500	Immunotherapy synergy	Bayer	2025

Key Clinical Findings

• ALSYMPCA Study (NCT00699751) [1]: Pivotal Phase III trial that validated XOFIGO's efficacy, demonstrating a median overall survival (OS) extension of 14.9 months versus 11.3 months in placebo. It also improved skeletal-related events (SREs) with a favorable safety profile.
• Recent Trials: Investigations into combination therapies (e.g., with immunotherapy and chemotherapeutics) aim to enhance efficacy and address resistance. Early-phase data suggest promising synergistic effects with checkpoint inhibitors.

Regulatory and Safety Highlights

• FDA Approval: 2013, based on ALSYMPCA with accelerated approval pathways.
• Safety Profile: Common adverse reactions include nausea, anemia, diarrhea, and thrombocytopenia. Rare but severe cases involve hematologic toxicity.
• Post-marketing Surveillance: Ongoing to monitor long-term safety, especially in combination regimens.

---

Market Analysis

Market Size & Growth Drivers

Aspect	Data/Estimate	Source/Notes
2022 Global Market Size	~$280 million	IQVIA, 2022
2027 Projected Market Size	~$560 million	CAGR: ~15%, MarketsandMarkets
Key Drivers	Increasing incidence of prostate cancer with bone metastasis, unmet need for targeted therapies, approval of combination regimens	—
Geographical Expansion	Europe, Asia-Pacific, Latin America	Regulatory approvals in select markets, growing healthcare infrastructure

Market Segmentation & Key Players

Segment	Description	Leading Companies	Market Share (2022)	Notes
Monotherapy	XOFIGO alone	Bayer	~40%	Established segment
Combination Therapy	XOFIGO + chemo, immunotherapy	Bayer, Novartis, Pfizer	~60%	Emerging, with increasing R&D
Palliative & Supportive Care	Managing SREs	Various	N/A	Complementary segment

Competitive Landscape

Compound / Therapy	Mechanism	Indications	Market Position	Key Differentiators	Cost (USD)
Radium-223 (XOFIGO)	Alpha-emitting radiopharmaceutical	mCRPC with bone metastases	Market leader	Proven survival benefit, well-established	~$11,000 per dose
Cabozantinib (Cabometyx)	Tyrosine kinase inhibitor	CRPC, bone metastases	Competing	Oral administration, diverse indications	~$14,000/month
Lutetium-177-PSMA (Pluvicto)	Radioligand therapy	mCRPC	Emerging	Target-specific, promising efficacy	~$29,000 per dose

Market Challenges & Opportunities

• Challenges: Reimbursement hurdles, competition from novel radioligand therapies, and patient selection complexities.
• Opportunities: Expansion into earlier treatment lines, combination strategies, and personalized therapy algorithms.

---

Projections and Future Outlook

Market Growth Forecast (2023-2027)

Year	Estimated Market Size (USD Millions)	Assumptions
2023	~$305	Continued adoption, approval of combination trials
2024	~$350	Entry of new indications, increased awareness
2025	~$410	Expansion in emerging markets, supportive policies
2026	~$490	Higher penetration, new clinical approvals
2027	~$560	Mature market with diversified uses

CAGR from 2022 to 2027: ~15%

Key Factors Impacting Market Trajectory

• Uptake of combination therapies enhancing efficacy.
• Expanding indications, including earlier disease stages.
• Regulatory approvals in international markets.
• Healthcare system adaptations and reimbursement policies.
• Ongoing clinical validation of enhanced survival benefits.

Potential Disruptors

| Disruptor | Impact | Timeline |

|---------------------------|---------|--------------|
| Novel radioligand therapies | Market share erosion | 2024-2026 |
| Gene therapies / immunotherapies | Therapeutic paradigm shift | 2025-2028 |
| Regulatory barriers | Slowed adoption | Ongoing |

---

Comparison with Competitors

Therapy	Indications	Mode of Action	Approval Year	Pivotal Trial Results	OS Benefit	Price (USD)
XOFIGO (Radium-223)	mCRPC with bone metastases	Alpha-emitter radiotherapy	2013	ALSYMPCA	+3.6 months	~$11,000/dose
Lutetium-177-PSMA	Advanced prostate cancer	Targeted radioligand	2022 (FDA)	VISION trial	Up to +4 months in some populations	~$29,000/dose
Cabozantinib	CRPC with bone metastases	Tyrosine kinase inhibitor	2016	METEOR trial	Median PFS: 5.5 vs. 2.7 months	~$14,000/month

Strategic Considerations for Stakeholders

• Pharmaceutical Companies: Focus on combination trial development to extend XOFIGO's market lead.
• Investors: Monitor approval timelines for emerging radioligand therapies, which could threaten monopolistic positioning.
• Regulators: Encourage international access through accelerated pathways and support data sharing for combination therapies.
• Healthcare Providers: Emphasize patient stratification to optimize outcomes with XOFIGO.

---

Key Takeaways

• Clinical efficacy of XOFIGO is well-established, with a median OS benefit of approximately 3.6 months over placebo, supported by robust trial data.
• Market potential is driven by increasing prostate cancer incidence and need for targeted therapies, with projected growth at a CAGR of ~15%.
• Regulatory landscape remains favorable, with ongoing trials focusing on combination regimens aiming to enhance efficacy.
• Competitive landscape is evolving, with emerging radioligand therapies posing potential challenges but also opportunities for strategic partnerships.
• Future projections suggest sustained growth through broader indications, international expansion, and combination strategies.

---

FAQs

1. What are the recent updates on clinical trials involving XOFIGO?

Recent trials focus on combination therapies integrating XOFIGO with immunotherapies like pembrolizumab (NCT03852615) and chemotherapeutics. Early results indicate potential synergistic efficacy, prompting phase III trials to validate these approaches.

2. How does XOFIGO compare with emerging radioligand therapies?

While XOFIGO has a proven survival benefit, therapies like Lutetium-177-PSMA (Pluvicto) demonstrate promising efficacy with a different targeting mechanism. The choice depends on patient eligibility, disease characteristics, and regulatory approvals.

3. What factors could influence the market growth for XOFIGO?

Key factors include clinical trial outcomes, regulatory decisions, reimbursement policies, and competition from other radioligand and immunotherapy options.

4. Are there any significant safety concerns with XOFIGO?

XOFIGO exhibits a manageable safety profile, with hematologic adverse events like anemia and thrombocytopenia being most common. Rare severe toxicities necessitate careful patient monitoring.

5. What are the prospects for expanding XOFIGO’s indications?

Ongoing trials aim to evaluate XOFIGO in earlier disease stages and in conjunction with other agents. Positive results could lead to label expansions and increased market penetration.

---

References

[1] Parker C, et al. (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 369(3):213–223.
[2] International Clinical Trials Registry Platform. (2023). Completed and ongoing clinical studies involving radium-223.
[3] MarketsandMarkets. (2022). Radiopharmaceuticals Market by Type and Application.
[4] IQVIA. (2022). Global Oncology Market Trends.